About US
Contact us
-
Pfizer sues Texas agency for leaking 'confidential' Medicaid pricing dealsPfizer has faced scrutiny for its drug pricing over the last year, but now it’s bringing some heat of its own to protect those numbers from prying eyes. The pharma giant last week sueda Texasagency, c2017/1/6
-
Teva sets aside $520M to settle bribery investigations by DOJ, SECTeva is trying to clean the slate on its history of allegedly paying bribes in foreign countries to boost sales. Having revamped its governance programs and set a new tone about bad behavior, it has n2017/1/5
-
DOJ's price-fixing investigation could lead to sizable liabilities, analyst saysWhile industry closely tracks developments on the Department of Justice price-fixing investigation into a host of generics companies, one influential analyst has run the numbers on potential liabiliti2017/1/5
-
DOJ pricing probe threatens $1B-plus fines, but few generics makers will face charges: AnalystsNews that the Justice Department is preparing criminal charges in its long-standing investigation into generic drug pricing hit those companies hard Thursday afternoon, wiping out $8.5 billion in mark2017/1/4
-
Top generics players and execs face DOJ investigation, charges: BloombergShare prices for leading generics companies took a big hit Thursday on news that the Department of Justice could file collusion charges by year’s end, a probe firstunveiledbyBloomberg. Companies incl2017/1/4
-
Why is Valeant's 'blockbuster' libido drug Addyi a dud? Shoddy marketing, investor lawsuit claimsWhen Valeant bought Sprout Pharmaceuticals and its controversial female libido drug Addyi, it agreed to a marketing blitz that would bring royalties to Sprout's former shareholders. Valeant bungled th2017/1/3
-
More Valeant up for bid? Beseiged pharma weighs $2.5B sale of eye-surgery bizAnother day, another Valeant asset sale rumor. Less than 24 hours after word got out that Valeant and Takeda were in Salix deal talks, the embattled drugmaker is said to be exploring a sale of its eye2017/1/3
-
Allergan to acquire Acelity’s regenerative medicine unit LifeCell for $2.9bnUS-based drugmaker Allergan has signed an agreement to acquire Acelity’s regenerative medicine unit LifeCell in a deal valued at $2.9bn. The acquisition will combine LifeCell's business, including it2016/12/30
-
AbbVie submits NDA to US FDA for pan-genotypic regimen of G/PGlobal biopharmaceutical company AbbVie has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for its investigational, pan-genotypic regimen of glecaprevir / pibrenta2016/12/30
-
US FDA approves Rubraca to treat advanced ovarian cancerThe US Food and Drug Administration (FDA) has granted approval to Rubraca (rucaparib) for the treatment of advanced ovarian cancer in women. The poly ADP-ribose polymerase (PARP) inhibitor Rubraca is2016/12/29